Allergic diseases are among the major causes of illness and disability for all ages in the United States. Food allergy affects about 6% to 8% of children under the age of four, and more than 3.7% of adults in the U.S. More than 23 million people in the United States have asthma. It accounts for ~500,000 hospitalizations each year, was responsible for 3,384 deaths in 2005 and has an annual economic cost of ~$20b. Intense research over the past 30 years has increased our understanding of the pathogenesis of asthma and other allergic diseases. These diseases are caused by an overzealous Th2 immune response to allergens in which immunoglobulin E (IgE) and mast cells play critical roles. Thus, aggregation of high affinity IgE receptor (Fc5RI) by allergen on mast cells results in rapid histamine release and the generation of lipids and cytokines, which are responsible for the manifestations of allergic diseases. The focus of our research has been to study G protein coupled receptor (GPCR) signaling in mast cells. It is generally accepted that agonist-induced GPCR phosphorylation by one or more of the G protein coupled receptor kinases (GRKs) is responsible for receptor desensitization. Unexpectedly, we found that silencing GRK2 expression in human mast cells substantially inhibits Fc5RI-mediated degranulation. Based on this finding, we hypothesize that GRK2 plays a novel role in allergic diseases by promoting Fc5RI signaling in mast cells.
In aim #1, we will generate murine bone marrow-derived mast cells (BMMC) with silencing or overexpression of GRK2 in vitro.
In aim #2, we will use mast cell "knock-in" approach to generate mice with mast cell-specific silencing/overexpression of GRK2. Passive systemic anaphylaxis (PSA), bronchoconstriction in precision cut murine lung slices and murine model of allergic asthma will be used to test the hypothesis that mast cell-specific expression of GRK2 is required for allergic responses in vivo. If the outcome of the proposed studies are realized it may provide novel approaches for the treatment of allergic diseases such as food allergy, anaphylaxis, rhinitis and asthma.

Public Health Relevance

Allergic diseases such as food allergy, anaphylaxis, rhinitis and asthma affect millions of Americans with billions of dollars in health care cost. In recent years, allergy prevalence and severity have been increasing dramatically world-wide. Mast cells release inflammatory mediators that cause the symptoms of asthma and other allergic diseases. This proposal is based on the identification of a novel signaling molecule that regulates mast cell function. We believe that proposed studies will generate significant new information on the regulation of mast cell function and may offer novel therapeutic approaches for the treatment of asthma and other allergic diseases.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Exploratory/Developmental Grants (R21)
Project #
5R21AI094896-02
Application #
8317532
Study Section
Special Emphasis Panel (ZRG1-IMM-M (02))
Program Officer
Dong, Gang
Project Start
2011-08-15
Project End
2014-07-31
Budget Start
2012-08-01
Budget End
2014-07-31
Support Year
2
Fiscal Year
2012
Total Cost
$240,000
Indirect Cost
$90,000
Name
University of Pennsylvania
Department
Pathology
Type
Schools of Dentistry
DUNS #
042250712
City
Philadelphia
State
PA
Country
United States
Zip Code
19104
Subramanian, Hariharan; Gupta, Kshitij; Parameswaran, Narayanan et al. (2014) Regulation of Fc?RI signaling in mast cells by G protein-coupled receptor kinase 2 and its RH domain. J Biol Chem 289:20917-27